These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 20685117)

  • 81. 2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
    Billamboz M; Suchaud V; Bailly F; Lion C; Andréola ML; Christ F; Debyser Z; Cotelle P
    Eur J Med Chem; 2016 Jul; 117():256-68. PubMed ID: 27105029
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Molecular features related to HIV integrase inhibition obtained from structure- and ligand-based approaches.
    de Carvalho LL; Maltarollo VG; de Lima EF; Weber KC; Honorio KM; da Silva AB
    PLoS One; 2014; 9(1):e81301. PubMed ID: 24416129
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Activities, crystal structures, and molecular dynamics of dihydro-1H-isoindole derivatives, inhibitors of HIV-1 integrase.
    Métifiot M; Maddali K; Johnson BC; Hare S; Smith SJ; Zhao XZ; Marchand C; Burke TR; Hughes SH; Cherepanov P; Pommier Y
    ACS Chem Biol; 2013 Jan; 8(1):209-17. PubMed ID: 23075516
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Cellular Immune Response Induced by DNA Immunization of Mice with Drug Resistant Integrases of HIV-1 Clade A Offers Partial Protection against Growth and Metastatic Activity of Integrase-Expressing Adenocarcinoma Cells.
    Isaguliants M; Krotova O; Petkov S; Jansons J; Bayurova E; Mezale D; Fridrihsone I; Kilpelainen A; Podschwadt P; Agapkina Y; Smirnova O; Kostic L; Saleem M; Latyshev O; Eliseeva O; Malkova A; Gorodnicheva T; Wahren B; Gordeychuk I; Starodubova E; Latanova A
    Microorganisms; 2021 Jun; 9(6):. PubMed ID: 34199989
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Resistance towards exonucleases of dinucleotides with stereochemically altered internucleotide phosphate bonds.
    Nair V; Pal S
    Bioorg Med Chem Lett; 2004 Jan; 14(1):289-91. PubMed ID: 14684345
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Discovery and Preclinical Profiling of GSK3839919, a Potent HIV-1 Allosteric Integrase Inhibitor.
    Parcella K; Wang T; Eastman K; Zhang Z; Yin Z; Patel M; Tu Y; Zheng BZ; Walker MA; Saulnier MG; Frennesson D; Bowsher M; Gillis E; Peese K; Belema M; Cianci C; Dicker IB; McAuliffe B; Ding B; Falk P; Simmermacher J; Parker DD; Sivaprakasam P; Kish K; Lewis H; Hanumegowda U; Jenkins S; Kadow JF; Krystal M; Meanwell NA; Naidu BN
    ACS Med Chem Lett; 2022 Jun; 13(6):972-980. PubMed ID: 35707159
    [TBL] [Abstract][Full Text] [Related]  

  • 87. KYNA Derivatives with Modified Skeleton; Hydroxyquinolines with Potential Neuroprotective Effect.
    Lőrinczi B; Szatmári I
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769362
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Bioisosteric Replacement as a Tool in Anti-HIV Drug Design.
    Dick A; Cocklin S
    Pharmaceuticals (Basel); 2020 Feb; 13(3):. PubMed ID: 32121077
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Hexafluoroisopropanol mediated benign synthesis of 2H-pyrido[1,2-a]pyrimidin-2-ones by using a domino protocol.
    Alsharif Z; Ali MA; Alkhattabi H; Jones D; Delancey E; Ravikumar PC; Alam MA
    New J Chem; 2017 Dec; 41(24):14862-14870. PubMed ID: 29430169
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
    Goethals O; Vos A; Van Ginderen M; Geluykens P; Smits V; Schols D; Hertogs K; Clayton R
    Virology; 2010 Jul; 402(2):338-46. PubMed ID: 20421122
    [TBL] [Abstract][Full Text] [Related]  

  • 91. HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations.
    Mouscadet JF; Arora R; André J; Lambry JC; Delelis O; Malet I; Marcelin AG; Calvez V; Tchertanov L
    J Mol Recognit; 2009; 22(6):480-94. PubMed ID: 19623602
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
    Baldanti F; Paolucci S; Gulminetti R; Brandolini M; Barbarini G; Maserati R
    J Med Virol; 2010 Jan; 82(1):116-22. PubMed ID: 19950236
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Discovery of potent HIV integrase inhibitors active against raltegravir resistant viruses.
    Le G; Vandegraaff N; Rhodes DI; Jones ED; Coates JA; Lu L; Li X; Yu C; Feng X; Deadman JJ
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5013-8. PubMed ID: 20685117
    [TBL] [Abstract][Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 5.